NAII vs USNA
Natural Alternatives International Inc. and Usana Health Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NAII | USNA |
|---|---|---|
| Revenue | $129.9M | $925.3M |
| Net income | $-13.6M | $10.8M |
| Gross margin | 7.2% | 78.3% |
| Net margin | −10.5% | 1.2% |
| Return on equity | −18.0% | 2.0% |
| Diluted EPS | −$2.28 | $0.58 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $2.3M | $8.5M |
| Equity | $68.4M | $533.1M |
| Net debt / equity | −0.33× | — |
| Current ratio | 2.06× | 2.24× |
| Revenue CAGR 5y | 1.8% | −4.0% |
| Profit CAGR 5y | — | −38.7% |
USNA bills 7.1× the revenue of NAII, and NAII closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NAII | USNA |
|---|---|---|
| FY2024 | $129.9M | $854.5M |
| FY2023 | $113.8M | $921.0M |
| FY2022 | $154.0M | $998.6M |
| FY2021 | $171.0M | $1.2B |
| FY2020 | $178.5M | $1.1B |
| FY2019 | $118.9M | $1.1B |
| FY2018 | $138.3M | $1.2B |
| FY2017 | $132.4M | $1.0B |
| FY2016 | $121.9M | $1.0B |
| FY2015 | $114.2M | $918.5M |
Net income by year
Bottom line
| Fiscal year | NAII | USNA |
|---|---|---|
| FY2024 | $-13.6M | $42.0M |
| FY2023 | $-7.2M | $63.8M |
| FY2022 | $2.5M | $69.3M |
| FY2021 | $10.7M | $116.5M |
| FY2020 | $10.8M | $124.7M |
| FY2019 | $-1.6M | $100.5M |
| FY2018 | $6.5M | $126.2M |
| FY2017 | $5.1M | $62.5M |
| FY2016 | $7.2M | $100.0M |
| FY2015 | $9.5M | $94.7M |
Advertisement
AdSense · Rectangle 336×280
More in this industry
Other pairs
The companies